<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute coronary syndrome: Terminology and classification</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute coronary syndrome: Terminology and classification</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute coronary syndrome: Terminology and classification</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph S Alpert, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term acute coronary syndrome (ACS) is applied to patients in whom there is a suspicion or confirmation of acute myocardial ischemia or infarction. Non-ST-elevation myocardial infarction (NSTEMI), ST-elevation MI (STEMI), and unstable angina are the three traditional types of ACS. However, the widespread use of the high-sensitivity troponin test has changed the diagnosis of unstable angina to NSTEMI in almost all patients formerly diagnosed with unstable angina. This has occurred because those patients formerly called unstable angina actually have abnormally elevated high-sensitivity troponin values. Traditionally, unstable angina was defined as clinical and electrocardiographic (ECG) findings in the absence of an elevated biomarker level. Few if any patients with clinical and ECG evidence of myocardial ischemia have normal high-sensitivity troponin levels. Indeed, they demonstrate elevated levels of this biomarker, thus confirming the presence of myocardial cell death induced by ischemia. Almost all of these patients do not show a STEMI pattern on their ECG, and so they should be diagnosed as an NSTEMI [<a href="#rid1">1</a>].</p><p>While some of the rationale to classify ACS patients as having NSTEMI or STEMI is historical, the central reason is that the clinical management for each of these differs. (See  <a class="medical medical_review" href="/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department"</a> and  <a class="medical medical_review" href="/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION OF MYOCARDIAL INFARCTION</span><span class="headingEndMark"> — </span>The 2018 joint task force of the European Society of Cardiology (ESC), American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Health Federation (WHF) defined MI, whether STEMI or NSTEMI, as the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia [<a href="#rid2">2</a>]. The joint task force further refined the definition of MI by developing a clinical classification according to the assumed proximate cause of the myocardial ischemia. This classification system is presented in detail separately. (See  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H2765105736"><span class="h1">STEMI AND NSTEMI</span><span class="headingEndMark"> — </span>The terms STEMI and NSTEMI are most correctly used in patients who present with clinical characteristics compatible with myocardial ischemia and who demonstrate elevated troponin levels in the blood (see  <a class="medical medical_review" href="/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a>). The terms are also used in patients found to have an elevated troponin level (with other evidence of ischemia such as symptoms or ECG changes) that was performed after a coronary revascularization procedure (see  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction", section on 'After revascularization'</a> and  <a class="medical medical_review" href="/d/html/1574.html" rel="external">"Periprocedural myonecrosis following percutaneous coronary intervention", section on 'Diagnosis'</a>).</p><p>Similarly, the terms are applied in the setting of MI after noncardiac surgery when other evidence of ischemia is present. However, management may differ slightly based on ECG changes and the clinical setting. (See  <a class="medical medical_review" href="/d/html/69.html" rel="external">"Perioperative myocardial infarction or injury after noncardiac surgery", section on 'Acute treatment'</a>.)</p><p>STEMI and NSTEMI, which require the finding of an elevated troponin, are distinguished from each other based on ECG characteristics (see  <a class="medical medical_review" href="/d/html/2125.html" rel="external">"ECG tutorial: Myocardial ischemia and infarction"</a> and  <a class="medical medical_review" href="/d/html/2095.html" rel="external">"Electrocardiogram in the diagnosis of myocardial ischemia and infarction"</a>). The distinction is important to the extent that early management differs (see <a class="local">'Introduction'</a> above). In patients with NSTEMI, the ECG on presentation may show no significant abnormalities, ST-segment depression or elevation (usually transient), or T wave inversion. ST-segment and/or T wave changes are often dynamic and can be transient.</p><p>Since an elevation in troponin using high-sensitivity assays may not be detectable for up to three hours after presentation, an NSTEMI is frequently not diagnosed during the initial evaluation of patients who present with suspected ischemic chest pain. However, subsequent analysis of blood troponin levels at a later time is abnormal, confirming the presence of a NSTEMI.</p><p>Most medical centers are using the high-sensitivity troponin test.</p><p class="headingAnchor" id="H2975162736"><span class="h1">UNSTABLE ANGINA</span><span class="headingEndMark"> — </span>As discussed above (see <a class="local">'Introduction'</a> above), the diagnosis of unstable angina is uncommon in the era of high-sensitivity troponin.</p><p class="headingAnchor" id="H4"><span class="h2">New onset angina</span><span class="headingEndMark"> — </span>The natural history of new onset angina depends in part upon the degree of exertion required to induce chest pain. Patients with new onset angina occurring only after heavy physical exertion, such as shoveling snow or lifting a 50 pound weight, have a prognosis similar to patients with chronic stable angina. In comparison, new angina occurring after minimal exercise or at rest, particularly if prolonged, carries a worse prognosis in the absence of intervention. A study evaluated short- and long-term outcomes of patients with acute coronary syndromes in clinical trials [<a href="#rid3">3</a>]. While one large trial of 8859 patients showed no difference in short- and long-term mortality in patients with STEMI versus NSTEMI (the latter population includes unstable angina patients), other trials showed a significant increase in mortality in STEMI patients.</p><p class="headingAnchor" id="H5"><span class="h2">Rest angina</span><span class="headingEndMark"> — </span>Rest angina, particularly if prolonged and/or associated with transient ST-segment changes &gt;0.05 mV, identifies patients at increased risk (<a class="graphic graphic_table graphicRef55745" href="/d/graphic/55745.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H6"><span class="h2">Early post-MI angina</span><span class="headingEndMark"> — </span>Early postinfarction angina (defined as chest pain occurring within 48 hours after an acute MI) is typically associated with complex lesions and/or persistent intracoronary thrombus and with more severe coronary disease [<a href="#rid4">4,5</a>]. The recurrent chest pain may signify either remaining viable myocardium in the infarct zone or a different area of myocardium at risk [<a href="#rid6">6</a>].</p><p>Angina occurring soon after an acute MI is associated with high risk in the absence of intervention [<a href="#rid5">5,7-9</a>]. This was illustrated in a report from the GUSTO-IIb trial [<a href="#rid8">8</a>]. Among 3513 patients with NSTEMI (using the old definition that did not include serum troponins), 36 percent had recurrent ischemia that was responsive to medical therapy in 79 percent. Patients with recurrent ischemia that was refractory or responsive to medical therapy had a higher rate of reinfarction at 30 days (22 and 7.2 versus 2.3 percent in those without recurrent ischemia) and six months. In addition, the occurrence of refractory ischemia was associated with a higher mortality compared with responsive ischemia or no ischemia at 30 days (16 versus 6 and 4.3 percent) and one year. Similar findings were noted among 4125 patients with an STEMI and in over 40,000 patients with an STEMI in GUSTO-I [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Postrevascularization angina</span><span class="headingEndMark"> — </span>Angina after percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) can reflect a procedural event or, over the long-term, restenosis after PCI, stenosis in a graft (usually with saphenous vein grafts), or progression of native disease. (See  <a class="medical medical_review" href="/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a> and  <a class="medical medical_review" href="/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a> and  <a class="medical medical_review" href="/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery"</a> and  <a class="medical medical_review" href="/d/html/1565.html" rel="external">"Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Periprocedural angina</span><span class="headingEndMark"> — </span>A periprocedural ischemic event may occur with or without symptoms, with or without troponin elevation, and either at the site of PCI or remotely. (See  <a class="medical medical_review" href="/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic chest pain (with or without troponin elevation) within 48 hours after stenting usually results from procedural events such as abrupt vessel closure (usually due to stent thrombosis or progression of an untreated dissection), transient coronary spasm, side branch occlusion, or distal embolization of atherosclerotic or thrombotic debris.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other patients have asymptomatic enzyme elevations indicative of procedural-related myocardial injury of a type 4 MI if the troponin level is above five times the upper reference limit, and there is clinical evidence of ischemia on the electrocardiogram or an event during or after PCI such as stent thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On occasion, periprocedural ischemia early after PCI may occur at the site of stenotic lesions not addressed at the time of the procedure.</p><p></p><p>Electrocardiographic changes are associated with a worse prognosis [<a href="#rid10">10</a>].</p><p>An important diagnostic consideration soon after PCI is the distinction between ischemic and nonischemic chest pain. Nonischemic chest pain is typically manifested at rest, without ECG changes or elevation of cardiac enzymes [<a href="#rid11">11,12</a>]. Most patients describe pain characteristics different from their typical angina (more localized and frequently pleuritic). This discomfort lasts for less than 72 hours in about 80 percent of patients, and less than two weeks in the remainder [<a href="#rid11">11</a>]. Overexpansion of the stent is thought to be responsible in most cases. (See  <a class="medical medical_review" href="/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p>Recurrent angina during the postoperative period after CABG is usually due to a technical problem with a graft or with early graft closure. It is therefore an indication for prompt catheterization with revascularization by PCI, if feasible. The diagnosis of recurrent ischemia may be difficult to make after CABG, since cardiac enzyme elevations occur as a result of the surgical procedure and since ECG changes may reflect postoperative pericardial inflammation. (See  <a class="medical medical_review" href="/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Late angina</span><span class="headingEndMark"> — </span>The delayed onset of angina (30 days or more after PCI) can reflect restenosis after PCI, graft stenosis after CABG, or progression of native disease. Affected patients typically present with the gradual and progressive return of effort angina. Prompt stress testing should be performed, since these patients are at increased risk. Stress radionuclide myocardial perfusion imaging or echocardiography is preferred over exercise ECG testing, since these modalities can document both the site and extent of ischemia. (See  <a class="medical medical_review" href="/d/html/1566.html" rel="external">"Role of stress testing after coronary artery revascularization"</a>.)</p><p>While less common, some patients with recurrent ischemia present with unstable angina. Such patients should be evaluated with cardiac catheterization after adequate medical stabilization.</p><p>NSTEMI can also occur in patients with prior CABG; such patients have an increased rate of significant coronary events [<a href="#rid13">13,14</a>]. This issue was best illustrated in the PURSUIT trial of almost 11,000 patients with a non-ST-ACS, 12 percent (1134 patients) of whom had a prior CABG [<a href="#rid13">13</a>]. Patients with a prior CABG had a significantly higher mortality at 30 days (5.2 versus 3.4 percent without a prior CABG, adjusted hazard ratio 1.45) and six months (8 versus 6.6 percent, adjusted hazard ratio 1.32). This difference may reflect a greater degree of cardiac disease.</p><p>The older the saphenous vein graft, the higher the likelihood that unstable angina is due to a culprit lesion within the graft (<a class="graphic graphic_figure graphicRef50106" href="/d/graphic/50106.html" rel="external">figure 1</a>) [<a href="#rid15">15</a>]. Grafts are more likely than native vessels to show total occlusion or thrombus, complications that are more refractory to medical therapy. Among patients who undergo PCI for saphenous vein graft disease, the development of restenosis is manifested by unstable angina presentation in as many as 25 percent of patients [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/1565.html" rel="external">"Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Absence of significant coronary disease</span><span class="headingEndMark"> — </span>In different clinical trials and the CRUSADE registry, 9 to 14 percent of patients with a non-ST-elevation ACS have either normal vessels or no vessel with ≥50 to 60 percent stenosis on coronary angiography [<a href="#rid17">17-23</a>].</p><p>Possible mechanisms for the absence of significant coronary disease in these patients include coronary thrombosis with rapid clot lysis, vasospasm, macro- and microemboli, coagulopathy, vasculitis, small vessel disease, coronary microvascular dysfunction, and myocarditis. The absence of significant coronary disease has also been described in patients with stable angina (see  <a class="medical medical_review" href="/d/html/1479.html" rel="external">"Microvascular angina: Angina pectoris with normal coronary arteries"</a>).</p><p>The characteristics of patients with ACS who have mild or no coronary disease was further examined in a study of 5767 patients with a non-ST-segment elevation ACS who were enrolled in the PURSUIT trial and who underwent angiography: 6 percent had mild coronary disease (&gt;0 to ≤50 percent stenosis) and 6 percent had no disease [<a href="#rid19">19</a>]. The strongest independent predictors of insignificant coronary disease were:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Female sex; a greater prevalence of mild or no coronary disease in women was also noted in the TACTICS-TIMI 18 trial (17 versus 9 percent in men) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of enrollment MI, prior angina, diabetes, or ST-segment depression.</p><p></p><p>Similar predictors of insignificant coronary disease, as well as lack of current/recent smoking, were found in the CRUSADE registry [<a href="#rid23">23</a>].</p><p>Patients with a non-ST-elevation ACS who do not have significant coronary disease have a better outcome than those with a culprit coronary lesion. (See  <a class="medical medical_review" href="/d/html/76.html" rel="external">"Risk stratification after non-ST elevation acute coronary syndrome", section on 'Absence of significant coronary disease'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3447.html" rel="external">"Patient education: Heart attack (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute coronary syndromes</strong> – Non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation MI (STEMI) are the two types of acute coronary syndromes (ACS). (See <a class="local">'STEMI and NSTEMI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unstable angina</strong> – Unstable angina is further categorized based on patient characteristics at the time of presentation. New onset, rest, and early post-MI are examples. (See <a class="local">'Unstable angina'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial infarction related to procedures</strong> – While these terms are most commonly applied to patients who develop symptoms during the course of their daily lives, they can also be used for patients who have undergone myocardial revascularization or noncardiac surgery. (See <a class="local">'STEMI and NSTEMI'</a> above and <a class="local">'Postrevascularization angina'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? Circulation 2013; 127:2452.</a></li><li><a class="nounderline abstract_t">Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018; 72:2231.</a></li><li><a class="nounderline abstract_t">Ye F, Winchester D, Jansen M, et al. Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review. Clin Med Res 2019; 17:11.</a></li><li><a class="nounderline abstract_t">Patel DJ, Gomma AH, Knight CJ, et al. Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina? An observational study of myocardial ischaemia and its relation to coronary anatomy. Eur Heart J 2001; 22:1991.</a></li><li><a class="nounderline abstract_t">Bosch X, Théroux P, Waters DD, et al. Early postinfarction ischemia: clinical, angiographic, and prognostic significance. Circulation 1987; 75:988.</a></li><li><a class="nounderline abstract_t">Schuster EH, Bulkley BH. Early post-infarction angina. Ischemia at a distance and ischemia in the infarct zone. N Engl J Med 1981; 305:1101.</a></li><li><a class="nounderline abstract_t">GISSI-3 APPI Study Group. Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study). Am J Cardiol 1996; 78:1191.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.</a></li><li><a class="nounderline abstract_t">Betriu A, Califf RM, Bosch X, et al. Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:94.</a></li><li><a class="nounderline abstract_t">Robbins MA, Marso SP, Wolski K, et al. Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. Am J Cardiol 1999; 84:1350.</a></li><li><a class="nounderline abstract_t">Kini AS, Lee P, Mitre CA, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol 2003; 41:33.</a></li><li><a class="nounderline abstract_t">Jeremias A, Kutscher S, Haude M, et al. Nonischemic chest pain induced by coronary interventions: a prospective study comparing coronary angioplasty and stent implantation. Circulation 1998; 98:2656.</a></li><li><a class="nounderline abstract_t">Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2002; 105:322.</a></li><li><a class="nounderline abstract_t">Kleiman NS, Anderson HV, Rogers WJ, et al. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry). Am J Cardiol 1996; 77:227.</a></li><li><a class="nounderline abstract_t">Chen L, Théroux P, Lespérance J, et al. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996; 28:1493.</a></li><li><a class="nounderline abstract_t">Chandrasekar B, Bourassa MG. Incidence and risk factors predictive of unstable angina resulting from restenosis after percutaneous angioplasty of saphenous vein grafts. Am Heart J 2000; 140:827.</a></li><li><a class="nounderline abstract_t">Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006; 166:1391.</a></li><li><a class="nounderline abstract_t">Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74:531.</a></li><li><a class="nounderline abstract_t">Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.</a></li><li><a class="nounderline abstract_t">Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.</a></li><li><a class="nounderline abstract_t">Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.</a></li><li><a class="nounderline abstract_t">Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.</a></li><li><a class="nounderline abstract_t">Patel MR, Chen AY, Peterson ED, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J 2006; 152:641.</a></li></ol></div><div id="topicVersionRevision">Topic 43 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775194" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Unstable angina: is it time for a requiem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153967" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fourth Universal Definition of Myocardial Infarction (2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160474" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Assessing Prognosis of Acute Coronary Syndrome in Recent Clinical Trials: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11603906" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Why is recurrent myocardial ischaemia a predictor of adverse outcome in unstable angina? An observational study of myocardial ischaemia and its relation to coronary anatomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3568314" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early postinfarction ischemia: clinical, angiographic, and prognostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7290117" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early post-infarction angina. Ischemia at a distance and ischemia in the infarct zone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960573" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799205" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426024" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614805" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12570941" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Postprocedure chest pain after coronary stenting: implications on clinical restenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851949" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nonischemic chest pain induced by coronary interventions: a prospective study comparing coronary angioplasty and stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11804987" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607398" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917263" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099984" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence and risk factors predictive of unstable angina resulting from restenosis after percutaneous angioplasty of saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16832004" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8074033" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973837" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475181" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419424" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12495392" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Benefit of an early invasive management strategy in women with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996828" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
